Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 phenotype prediction from genotype: which system is the best?

Clinical pharmacology and therapeutics - 1 Feb 2008

Kirchheiner J

Abstract excerpt

Genotyping of the polymorphic cytochrome P450 (CYP) 2D6 gene is used increasingly in clinical practice. Several psychiatric hospitals already use CYP2D6 testing before treating a patient with antidepressant or antipsychotic drug therapy. In other fields of drug therapy, such as for breast cancer, CYP2D6 status has been reported to be an independent predictor for the outcome with tamoxifen. Thus, a more favorable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Antineoplastic Agents, Hormonal
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Dextromethorphan

Share to Linear Models

Share to Patient Selection

Share to Tamoxifen

Source

Identifiers

PMID: 18202689
DOI: 10.1038/sj.clpt.6100455

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 phenotype prediction from genotype: which system is the best?PMID 18202689Read ↗

Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.Semantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.Semantic proximity Read ↗

Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.